

EN

E-000488/2025

Answer given by Ms Zaharieva
on behalf of the European Commission
(15.5.2025)

1. Since 1996, Israel's association to the EU framework programmes for research and innovation (R&I) has been a success story with clear mutual benefits across various priority areas including information and communication technologies, health, advanced manufacturing, climate change and energy, as well as biotechnology. At this stage, it is premature to discuss which countries would be allowed to participate in or offered association to the successor of the current framework programme for R&I and under which terms as it is still to be scrutinised and adopted by the co- legislators, based on a proposal that is yet to be adopted by the Commission.
2. In accordance with Article 2 Treaty on European Union, the EU is founded on the values of *inter alia* respect for human rights. In consequence and in application of relevant EU, national and international law¹, the EU will continue to reaffirm its commitment to the protection and promotion of human rights including in R&I related activities, applicable to all participants in the R&I framework programmes regardless of their nationality.
3. Currently, any R&I activities carried out under Horizon Europe² must have an exclusive focus on civil applications, as set forth in applicable rules and in particular in the Horizon Europe Regulation³. During the implementation of Horizon Europe projects, all beneficiaries must ensure that the activities under the action comply with these rules.

¹ Including the Charter of Fundamental Rights of the European Union and the European Convention for the Protection of Human Rights and Fundamental Freedoms and its Supplementary Protocols.

² https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe_en

³ <https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R0695>, OJ L 170, 12.5.2021, p. 1–68.